Literature DB >> 25245291

Inhibition of adipogenesis and leptin production in 3T3-L1 adipocytes by a derivative of meridianin C.

Yu-Kyoung Park1, Tae-Yoon Lee2, Jong-Soon Choi3, Victor Sukbong Hong4, Jinho Lee5, Jong-Wook Park6, Byeong-Churl Jang7.   

Abstract

Meridianin C, a marine alkaloid, is a potent protein kinase inhibitor and has anti-cancer activity. We have recently developed a series of meridianin C derivatives (compound 7a-7j) and reported their proviral integration Moloney Murine Leukemia Virus (pim) kinases' inhibitory and anti-proliferative effects on human leukemia cells. Here we investigated the effect of these meridianin C derivatives on adipogenesis. Strikingly, among the derivatives tested, compound 7b most strongly inhibited lipid accumulation during the differentiation of 3T3-L1 preadipocytes into adipocytes. However, meridianin C treatment was largely cytotoxic to 3T3-L1 adipocytes. On mechanistic levels, compound 7b reduced not only the expressions of CCAAT/enhancer-binding protein-α (C/EBP-α), peroxisome proliferator-activated receptor-γ (PPAR-γ), and fatty acid synthase (FAS) but also the phosphorylation levels of signal transducer and activator of transcription-3 (STAT-3) and STAT-5 during adipocyte differentiation. Moreover, compound 7b repressed leptin, but not adiponectin, expression during adipocyte differentiation. Collectively, these findings demonstrate that a meridianin C derivative inhibits adipogenesis by down-regulating expressions and/or phosphorylations of C/EBP-α, PPAR-γ, FAS, STAT-3 and STAT-5.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adipogenesis; C/EBP-α; Meridianin C derivative; PPAR-γ; STAT-3/5

Mesh:

Substances:

Year:  2014        PMID: 25245291     DOI: 10.1016/j.bbrc.2014.09.050

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Meridianin D Analogues Display Antibiofilm Activity against MRSA and Increase Colistin Efficacy in Gram-Negative Bacteria.

Authors:  William M Huggins; William T Barker; James T Baker; Nicholas A Hahn; Roberta J Melander; Christian Melander
Journal:  ACS Med Chem Lett       Date:  2018-05-25       Impact factor: 4.345

2.  Repurposing Eukaryotic Kinase Inhibitors as Colistin Adjuvants in Gram-Negative Bacteria.

Authors:  William T Barker; Ansley M Nemeth; Sara M Brackett; Akash K Basak; Courtney E Chandler; Leigh A Jania; William J Zuercher; Roberta J Melander; Beverly H Koller; Robert K Ernst; Christian Melander
Journal:  ACS Infect Dis       Date:  2019-09-04       Impact factor: 5.084

Review 3.  Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives.

Authors:  Palma Lamonaca; Giulia Prinzi; Aliaksei Kisialiou; Vittorio Cardaci; Massimo Fini; Patrizia Russo
Journal:  Mar Drugs       Date:  2017-03-20       Impact factor: 5.118

4.  AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes.

Authors:  Yu-Kyoung Park; Brice Wilfried Obiang-Obounou; Kyung-Bok Lee; Jong-Soon Choi; Byeong-Churl Jang
Journal:  J Cell Mol Med       Date:  2018-02-14       Impact factor: 5.310

Review 5.  Ascidian Toxins with Potential for Drug Development.

Authors:  Dianne J Watters
Journal:  Mar Drugs       Date:  2018-05-13       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.